Pan‑cancer analysis of transmembrane protease serine 2 and cathepsin L that mediate cellular SARS‑CoV‑2 infection leading to COVID-19 by Katopodis, Periklis et al.
INTERNATIONAL JOURNAL OF ONCOLOGY  57:  533-539,  2020
Abstract. Severe acute respiratory syndrome (SARS) 
coronavirus-2 (SARS-CoV2) is the cause of a new disease 
(COVID-19) which has evolved into a pandemic during the 
first half of 2020. Older age, male sex and certain underlying 
diseases, including cancer, appear to significantly increase 
the risk for severe COVID‑19. SARS‑CoV‑2 infection of host 
cells is facilitated by the angiotensin-converting enzyme 2 
(ACE-2), and by transmembrane protease serine 2 (TMPRSS2) 
and other host cell proteases such as cathepsin L (CTSL). 
With the exception of ACE‑2, a systematic analysis of these 
two other SARS-CoV2 infection mediators in malignancies 
is lacking. Here, we analysed genetic alteration, RNA 
expression, and DNA methylation of TMPRSS2 and CTSL 
across a wide spectrum of tumors and controls. TMPRSS2 
was overexpressed in cervical squamous cell carcinoma 
and endocervical adenocarcinoma, colon adenocarcinoma, 
prostate adenocarcinoma (PRAD), rectum adenocarcinoma 
(READ), uterine corpus endometrial carcinoma and uterine 
carcinosarcoma, with PRAD and READ exhibiting the 
highest expression of all cancers. CTSL was upregulated 
in lymphoid neoplasm diffuse large B-cell lymphoma, 
oesophageal carcinoma, glioblastoma multiforme, head 
and neck squamous cell carcinoma, lower grade glioma, 
pancreatic adenocarcinoma, skin cutaneous melanoma, 
stomach adenocarcinoma, and thymoma. Hypo‑methylation 
of both genes was evident in most cases where they have been 
highly upregulated. We have expanded on our observations 
by including data relating to mutations and copy number 
alterations at pan‑cancer level. The novel hypotheses that are 
stemming out of these data need to be further investigated 
and validated in large clinical studies.
Introduction
Severe acute respiratory syndrome (SARS) coronavirus-2 
(SARS‑CoV2) is the cause of COVID‑19, which was first iden-
tified at the end of 2019 and has evolved into a pandemic during 
the following months (1). Based on increasing data, older age 
and male sex predispose to severe COVID‑19, whilst a number 
of underlying diseases/conditions are also directly related 
with significantly higher risk for adverse clinical outcomes 
from COVID‑19 (1). The latter include diabetes, hypertension, 
obesity, immunosuppression, asthma, and chronic obstructive 
pulmonary disease (1).
Entry of SARS-CoV2 into its host cells is facilitated by 
its spike proteins which bind to the angiotensin-converting 
enzyme 2 (ACE‑2) (2). Moreover, the spike viral proteins 
are primed by the transmembrane protease serine 2 
(TMPRSS2) (2). As such, SARS‑CoV2 infection of host cells is 
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Figure 1. SARS‑CoV2 attaches to the ACE‑2 receptor and it can be taken into the host cell in endosomes where it can be cleaved and activated by CTSL 
proteases. Moreover, TMPRSS2 is co‑expressed with ACE‑2 on the cell membrane and it can prime the spike viral proteins, thus activating the fusion of the 
virus with the membrane lipid layer and facilitating the uptake into the host cell. ACE‑2, angiotensin‑converting enzyme 2; CTSL, cathepsin L; TMPRSS2, 
transmembrane protease serine 2.
Figure 2. RNA expression aberration of CTSL in tumors. (A) the gene expression profile across all tumor samples and paired normal tissues, each dot 
represents expression of samples. (B) The gene expression profile across all tumor samples and paired normal tissues. The height of bar represents the median 
expression of certain tumor type or normal tissue. CTSL, cathepsin L.
Figure 3. RNA expression aberration of TMPRSS2 in tumors. (A) the gene expression profile across all tumor samples and paired normal tissues, each dot 
represents expression of samples. (B) The gene expression profile across all tumor samples and paired normal tissues. The height of bar represents the median 
expression of certain tumor type or normal tissue. TMPRSS2, transmembrane protease serine 2.
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facilitated by the cleavage of the spike proteins by TMPRSS2 
and host cell proteases, such as cathepsin L (CTSL) (Fig. 1) (3).
Cancer has been identified as a risk factor for severe 
COVID‑19, as many patients can be immunocompromised (4). 
In a very recent robust systematic analysis, Chai et al curated 
a pan‑cancer analysis of ACE‑2 detailing the expression and 
mutations across a wide spectrum of tumors (5). Following 
the same approach with this elegant study, here we expanded 
on these excellent observations by curating data for the other 
two mediators of SARS-CoV-2 infection, namely CTSL and 
TMPRSS2.
Materials and methods
Bioinformatic analysis. TMPRSS2 and CTSL were vali-
dated in The Cancer Genome Atlas (TCGA), GEPIA 
(http://gepia.cancer‑pku.cn/), UALCAN (http://ualcan.path.
uab.edu/cgi-bin/ualcan‑res.pl). The pan‑cancer cohort of 
TCGA was downloaded through cBioPortal (https://www.
cbioportal.org/). The datasets used for the two genes were: 
ACC, adrenocortical carcinoma; BLCA, bladder urothelial 
carcinoma; BRCA, breast invasive carcinoma; CESC, cervical 
squamous cell carcinoma and endocervical adenocarcinoma; 
Figure 4. Correlation of CTSL expression with methylation status. COAD and READ had lower expression in tumors (A, red) due to higher methylation 
status (B, red). The opposite happens on STAD with the lower methylation, to allow higher CTSL expression. In LHIC there was no significant difference in 
normal to tumor expression even if the methylation is higher in the cancer samples (P=1.47e‑07). CTSL, cathepsin L; COAD, colon adenocarcinoma; READ, 
rectum adenocarcinoma; STAD, stomach adenocarcinoma; LHIC, liver hepatocellular carcinoma.
Figure 5. Correlation of TMPRSS2 expression with methylation status. PRAD and READ had higher expression in tumors (A, red) due to lower methylation 
status (B, red). The opposite happens on BRCA and LUSC with the higher methylation, to decrease the expression of TMPRSS2 in tumors. TMPRSS2, trans-
membrane protease serine 2; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; BRCA, breast invasive carcinoma; LUSC, lung squamous 
cell carcinoma.
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CHOL, cholangio carcinoma; COAD, colon adenocarcinoma; 
DLBC, lymphoid neoplasm diffuse large B‑cell lymphoma; 
ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; 
HNSC, head and neck squamous cell carcinoma; KICH, kidney 
chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, 
kidney renal papillary cell carcinoma; LAML, acute myeloid 
leukemia; LGG, brain lower grade glioma; LIHC, liver hepato-
cellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung 
squamous cell carcinoma; MESO, mesothelioma; OV, ovarian 
serous cystadenocarcinoma; PAAD, pancreatic adenocarci-
noma; PCPG, pheochromocytoma and paraganglioma; PRAD, 
prostate adenocarcinoma; READ, rectum adenocarcinoma; 
SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, 
stomach adenocarcinoma; TGCT, testicular germ cell tumors; 
THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine 
corpus endometrial carcinoma; UCS, uterine carcinosarcoma 
and UVM, uveal melanoma.
Results and Discussion
In TCGA datasets for all cancers, CTSL was upregulated in 
DLBC, ESCA, GBM, HNSC, LGG, PADD, SKCM, STAD 
and THYM, while it has lower expression than normal in 
COAD, LAML and READ (Fig. 2A and B). On the other hand, 
TMPRSS2 was upregulated in CESC, COAD, KICH, PRAD, 
READ, UCEC and UCS, with PRAD and READ exhibiting 
the highest expression of all cancers (Fig. 3A and B).
Subsequently, the expression of these two genes from 
GEPIA were correlated with the methylation status using 
the Ualcan database. For most of the cancers there was a 
strong correlation of the gene expression with its promoter 
methylation status in agreement with the findings for 
ACE‑2 (5). CTSL in COAD and READ has a higher beta 
value; hence, lower expression of the gene, while in STAD, 
the lower methylation of the promoter, leads to higher 
Figure 6. CTSL RNA expression in tissues. Consensus transcript expression levels for each gene were summarized in 74 human tissues based on tran-
scriptomics data from three sources: HPA, GTEx and FANTOM5. The consensus NX value for each gene and organ/tissue represents the maximum NX 
value in the three data sources Color‑coding is based on tissue groups, each consisting of tissues with functional features in common. The data include 
10,953 patients/10,967 samples in 32 cancer datasets. CTSL, cathepsin L; HPA, Human Protein Atlas; GTEx, Genotype‑Tissue Expression; FANTOM5, the 
Functional Annotation of Mammalian Genomes 5; NX, normalized expression.
Figure 7. TMPRSS2 RNA expression in tissues. Consensus transcript expression levels for each gene were summarized in 74 human tissues based on transcrip-
tomics data from three sources: HPA, GTEx and FANTOM5. The consensus normalized expression (NX) value for each gene and organ/tissue represents the 
maximum NX value in the three data sources. Color‑coding is based on tissue groups, each consisting of tissues with functional features in common The data 
include 10,953 patients/10,967 samples in 32 studies. HPA, Human Protein Atlas; GTEx, Genotype‑Tissue Expression; FANTOM5, the Functional Annotation 
of Mammalian Genomes 5; NX, normalized expression.
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gene expression (Fig. 4A and B). Five cancers were found 
to have lower methylation than normal for the CTSL, and 
seven cancers for the TMPRSS2. In LUSC and BRCA, the 
very high methylation rate of the TMPRSS2 gene leads to 
a very low expression level (Fig. 5A and B), while the very 
low methylation rate in PRAD and READ lead to very high 
numbers of gene transcripts.
Moreover, using the Human Protein Atlas analysis, of 
the consensus transcript expression levels that combines the 
Human Protein Atlas (HPA), Genotype‑Tissue Expression; 
(GTEx) and the Functional Annotation of Mammalian 
Genomes 5 (FANTOM5) datasets, the expression of these two 
genes in organ/tissue samples were examined. CTSL is highly 
expressed in the placenta, adipose, appendix and lung tissue 
(Fig. 6). TMPRSS2 is highly expressed in prostate [indeed, 
TMPRSS2 and PCA are utilized as biomarkers for prostate 
cancer (6)], stomach, colon and small intestine tissues (Fig. 7).
Furthermore, using the cBioportal pan-cancer panel, 
the region and the types of mutations were identified which 
these two genes have in all the examined cancer types 
(Figs. 8A and 9A). Most of the CTSL mutations are lying on 
the peptidase region and are mostly found in CESC, ESCA, 
Mature B‑cell Neoplasms, Melanoma and COAD (Fig. 8B). 
Of note, in most of the cancers the majority of the patients had 
deletions and partly some gains and amplifications (Fig. 8C). 
TMPRSS2 mutations were lying across the whole gene region 
and mostly consist of gene fusions (TMPRSS2-ERG) in pros-
tate adenocarcinoma (Fig. 9B and C).
Figure 8. (A) CTSL mutations were distributed across the CTSL gene (cBioPortal) with 8 hot spot mutation sites in TCGA cohort using cBioPortal and 
3d hotspots (12). Mutation diagram circles are colored with respect to the corresponding mutation types. In case of different mutation types at a single position, 
color of the circle is determined with respect to the most frequent mutation type. Mutation types and corresponding color codes are as follows: green: Missense 
Mutations; black: Truncating Mutations. (B) The relevance of genetic disorders and CTSL expression where it is shown that mutations were not relevant to 
RNA expression. (C) DNA copy variation were not statistically relevant to RNA CTSL expression. CTSL, cathepsin L; TCGA, The Cancer Genome Atlas.
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Finally, examination of the overall survival (OS) of 
all cancers, showed that CTSL low expression in KIRC 
(P=0.0001) has poor prediction for the patients, while low 
expression of CTSL in LUSC (P=0.0077) had better prognosis. 
High expression of TMPRSS2 in BRCA, SARC and UM had 
poor prediction for the patients, while gene expression was 
not statistically relevant for the patients of the other types of 
cancers (Figs. S1‑S4).
Of note, neither of the two proteins were differentially regu-
lated in LUAD; a comorbidity of severe COVID‑19 contrary to 
ACE‑2 (7). TMPRSS2 is significantly upregulated in prostate 
cancer, where it harbors gene fusion events, as documented 
in this study. While preparing this report, another interesting 
study was published which corroborated the expression of 
TMPRSS2 in the prostate. In this study, the authors have put 
forward the question of whether the TMPRSS2 increased 
expression in prostate is involved with the documented sexual 
dimorphism of COVID‑19 (8). This is an exciting hypothesis 
that needs to be studied further given that the clinical data 
indicate that male sex is among the risk factors for adverse 
COVID‑19 related outcomes.
In our analysis we also demonstrate that the pancreas is 
riddled with deep deletions for TMPRSS2 where ACE-2 is 
co‑expressed. Interestingly, Liu et al (9) have recently shown 
that ACE‑2 expression in the pancreas may lead to pancreatic 
damage following SARS‑CoV‑2 infection. For CTSL, higher 
expression was noted in the human placenta where ACE‑2 is 
also co‑expressed (10). This finding warrants further investiga-
tion into the role of these viral entry mediators in placentation, 
vertical transmission of SARS-CoV-2 to the fetus, as well as 
Figure 9. (A) TMPRSS2 mutations were distributed across the TMPRSS2 gene (cBioPortal) (12). Mutation diagram circles are colored with respect to the 
corresponding mutation types. In case of different mutation types at a single position, color of the circle is determined with respect to the most frequent muta-
tion type. Mutation types and corresponding color codes are as follows: green: Missense mutations; black: Truncating mutations. (B) The relevance of genetic 
disorders and TMPRSS2 expression were as shown, in prostate cancer there is a 30% fusion of the gene and in the stomach adenocarcinoma 8% deep deletion. 
(C) DNA copy variation were not statistically relevant to RNA TMPRSS2 expression and as shown, many pancreatic cancer patients had deep deletions. CTSL, 
cathepsin L; TMPRSS2, transmembrane protease serine 2.
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their potential involvement in maternal and neonatal compli-
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